CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia

Autor: Johan Maertens, W Zeijlemaker, Alexander N Snel, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, D Veldhuizen, Angèle Kelder, Bob Löwenberg, Peter J. M. Valk, Jacqueline Cloos, Frank Preijers, Yvonne J M Oussoren-Brockhoff, Gerrit Jan Schuurhuis, Dimitri Breems, Jannemieke C Carbaat-Ham, Markus G. Manz, Willemijn J Scholten, Mojca Jongen-Lavrencic, Tim Grob, Rosa Meijer, Jennichjen Slomp, Thomas Pabst, Diana Hanekamp, Vincent H.J. van der Velden

Publikováno v: Leukemia, 33, 5, pp. 1102-1112
Zeijlemaker, W, Grob, T, Meijer, R, Hanekamp, D, Kelder, A, Carbaat-Ham, J C, Oussoren-Brockhoff, Y J M, Snel, A N, Veldhuizen, D, Scholten, W J, Maertens, J, Breems, D A, Pabst, T, Manz, M G, van der Velden, V H J, Slomp, J, Preijers, F, Cloos, J, van de Loosdrecht, A A, Löwenberg, B, Valk, P J M, Jongen-Lavrencic, M, Ossenkoppele, G J & Schuurhuis, G J 2019, ' CD34 + CD38 − leukemic stem cell frequency to predict outcome in acute myeloid leukemia ', Leukemia, vol. 33, no. 5, pp. 1102-1112 . https://doi.org/10.1038/s41375-018-0326-3
Leukemia, 33(5), 1102-1112. Nature Publishing Group
Leukemia, 33, 1102-1112

Current risk algorithms are primarily based on pre-treatment factors and imperfectly predict outcome in acute myeloid leukemia (AML). We introduce and validate a post-treatment approach of leukemic stem cell (LSC) assessment for prediction of outcome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2a6d40ee244c2dab3c8ec30912e8e22
https://doi.org/10.1038/s41375-018-0326-3

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia

Autor: W Zeijlemaker, Jacqueline Cloos, Angèle Kelder, Gerrit Jan Schuurhuis

Publikováno v: Current Protocols in Cytometry
Current Protocols in Cytometry, 91(1):e66. John Wiley and Sons Inc.
Zeijlemaker, W, Kelder, A, Cloos, J & Schuurhuis, G J 2019, ' Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia ', Current Protocols in Cytometry, vol. 91, no. 1, e66 . https://doi.org/10.1002/cpcy.66

Half of the patients with acute myeloid leukemia (AML), who achieve complete remission after chemotherapy treatment, will ultimately experience a relapse. Measurable residual disease (MRD) is an important post‐treatment risk factor in AML, because

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5be0eecd88747c3d8cd95062eba9b1
https://pubmed.ncbi.nlm.nih.gov/31763792

Tumor heterogeneity makes AML a 'moving target' for detection of residual disease

Autor: Gerrit Jan Schuurhuis, W Zeijlemaker, Jan-Willem Gratama

Publikováno v: Cytometry Part B: Clinical Cytometry. 86:3-14

Detection of minimal residual disease is recognized as an important post-therapy risk factor in acute myeloid leukemia patients. Two most commonly used methods for residual disease monitoring are real-time quantitative polymerase chain reaction and m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c5140ffcbd8931743faf7f875e66281
https://doi.org/10.1002/cyto.b.21134

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia

Autor: Gerrit Jan Schuurhuis, Arjo P Rutten, Willemijn J Scholten, W Zeijlemaker, Alexander N Snel, Monique Terwijn, Thomas Pabst, Angèle Kelder, Gregor Verhoef, Bob Löwenberg, Sonja Zweegman, Gert J. Ossenkoppele

Publikováno v: PLoS ONE, Vol 9, Iss 9, p e107587 (2014)
PLoS ONE
Terwijn, M, Zeijlemaker, W, Kelder, A, Rutten, A P, Snel, A N, Scholten, W J, Pabst, T, Verhoef, G, Lowenberg, B, Zweegman, S, Ossenkoppele, G J & Schuurhuis, G J 2014, ' Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia ', PLoS ONE, vol. 9, no. 9, e107587 . https://doi.org/10.1371/journal.pone.0107587
PloS one
PLoS One (print), 9(9). Public Library of Science
Terwijn, Monique; Zeijlemaker, Wendelien; Kelder, Angèle; Rutten, Arjo P; Snel, Alexander N; Scholten, Willemijn J; Pabst, Thomas; Verhoef, Gregor; Löwenberg, Bob; Zweegman, Sonja; Ossenkoppele, Gert J; Schuurhuis, Gerrit J (2014). Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS ONE, 9(9), e107587. Public Library of Science 10.1371/journal.pone.0107587
PLoS ONE, 9(9):e107587. Public Library of Science

INTRODUCTION Treatment failure in acute myeloid leukemia is probably caused by the presence of leukemia initiating cells, also referred to as leukemic stem cells, at diagnosis and their persistence after therapy. Specific identification of leukemia s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2035acafc097f4819538d5936855de6d
http://europepmc.org/articles/PMC4171508?pdf=render

Transurethral Marsupialization of a Medial Prostatic Cyst in Patients with Prostatitis-Like Symptoms

Autor: Bram Y. W. Zeijlemaker, Tom A. Boon, Bart Ph Schrier, Pieter Dik, Tycho M.W.T. Lock

Publikováno v: Journal of Urology. 155:1301-1304

Purpose: The results of transurethral marsupialization as treatment for medial prostatic cysts were assessed.Materials and Methods: Between June 1992 and August 1994 we performed transrectal ultrasound on 704 patients with symptoms of bladder outlet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::200fcbcc5203655898221b4d6563cc1a
https://doi.org/10.1016/s0022-5347(01)66251-7